Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
ApexOnco Front Page
Recent articles
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
The move comes after a death in the Alpha-3 cema-cel study.
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
The first data are dribbled out, but cross-trial comparisons look uninspiring.
